BC Extra | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital co-led the round, which...
BC Extra | Aug 28, 2017
Financial News

Akeso raises $45M in series B

Akeso Biopharma Inc. (Zhongshan, China) raised RMB300 million ($45.2 million) in a series B round led by Shenzhen GTJA Investment Group. Existing investors Shenzhen Capital, Qianhai Parent Fund and Qianhai TRI Wise Capital participated. In...
BC Week In Review | Dec 21, 2015
Company News

Akeso, Merck deal

Akeso granted Merck exclusive, worldwide rights to develop and commercialize AK-107 . The product is an immune checkpoint blocking antibody in preclinical development to treat cancer. Akeso will receive an undisclosed upfront payment and is eligible...
Items per page:
1 - 3 of 3